All In Biotech

Free tool

FAERS Monitor: Datroway

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761394 or its brand name (Datroway, Datopotamab Deruxtecan-Dlnk). Reports on generic versions are filed under their own applications.

Reports

859

Serious

553

64% of reports

Hospitalization

137

Death reported

173

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • disease progression256
  • stomatitis146
  • off label use122
  • death51
  • no adverse event46
  • nausea40
  • fatigue33
  • dry eye32
  • interstitial lung disease31
  • dyspnoea26
  • rash24
  • pneumonitis23
  • cough21
  • alopecia19
  • mucosal inflammation19

Reports by year received

View as table
YearReports
20222
20234
20242
2025321
2026530

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,300 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
stomatitisSignal14659.151.08,282
disease progressionSignal25653.147.913,077
pneumonitisSignal2320.713.8412
mucosal inflammationSignal1917.811.4285
dry eyeSignal3215.711.2427
interstitial lung diseaseSignal3115.711.1412
no adverse eventSignal466.24.7198
off label useSignal1223.42.9214
alopeciaSignal192.41.514
cough211.81.27
death511.41.17
rash241.30.92
nausea401.20.92
dyspnoea261.10.80
fatigue331.00.70

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.